Inhibitor Therapeutics Flags Going Concern, $3M Default Judgment, and FDA Path Forward
INTI has more than doubled off its 52-week low of $0.034.
Summary
Inhibitor Therapeutics' Q2 2026 filing reveals a going concern warning with only $515,758 in cash, a $3.0 million default judgment against an investor, and an FDA Type C meeting scheduled for written responses by end of September 2026.
Key Events · Earnings and Guidance · INTI
-
Going Concern Warning
Cash and cash equivalents fell to $515,758 as of June 30, 2026, from $2,375,493 at December 31, 2025. Management projects insufficient liquidity to sustain operations through one year, raising substantial doubt about the company's ability to continue as a going concern.
-
$3M Default Judgment
On August 3, 2026, the Delaware Court of Chancery awarded a default judgment of $3.0 million plus attorney's fees and interest against an institutional investor that failed to fund a securities purchase agreement. Collection is uncertain and no receivable has been recorded.
-
FDA Type C Meeting
The FDA granted a Type C meeting request on July 23, 2026, and will provide written responses by the end of September 2026 regarding the proposed surgically eligible endpoint for itraconazole in BCCNS. A negative response could require additional clinical trials the company cannot fund.
-
Provisional Patent Filed
On August 14, 2026, the company filed a provisional U.S. patent application covering a novel oral itraconazole formulation developed with Avior Bio, potentially extending protection beyond the 2029 expiration of the licensed JHU patent.
Analysis · INTI · Life Sciences
With cash down to $515,758, the company has issued a going concern warning. A $3.0 million default judgment against an institutional investor could provide relief, though collection remains uncertain. Meanwhile, the FDA has granted a Type C meeting with written responses expected by the end of September 2026—a critical milestone for the itraconazole program.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INTI was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $14.1M. The 52-week trading range was $0.03 to $0.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.